A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.

[1]  E. Sandoya,et al.  Ambulatory Blood Pressure , 1999 .

[2]  S. Oparil,et al.  Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. , 1998, The American journal of cardiology.

[3]  P. Morsing,et al.  A024 Candesartan causes a long-lasting antagonism of the angiotensin II receptor mediated contractile effects in isolated vascular preparations: A comparison with losartan and its active metabolite (EXP 3174) , 1998 .

[4]  L. Ruilope,et al.  A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension , 1998, Journal of Human Hypertension.

[5]  P. Lagerström,et al.  Encapsulation of Commercially Available Losartan for Blinding Purposes Does Not Affect its Bioavailability , 1998, Clinical drug investigation.

[6]  S. Oparil,et al.  Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. , 1998, The American journal of cardiology.

[7]  L Guize,et al.  Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. , 1997, Hypertension.

[8]  H. Heuer,et al.  Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. , 1997, Journal of human hypertension.

[9]  S. Magin,et al.  Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. , 1997, Journal of human hypertension.

[10]  D. Elmfeldt,et al.  Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. , 1997, Journal of human hypertension.

[11]  K. Kubo,et al.  Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. , 1997, European journal of pharmacology.

[12]  White.  Clinical relevance of ambulatory versus clinic blood pressure when evaluating antihypertensive therapy. , 1996, Blood pressure monitoring.

[13]  D. Snavely,et al.  A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. , 1995, Hypertension.

[14]  G Parati,et al.  Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment: additional information from a large data base. , 1995, Blood pressure.

[15]  D. Snavely,et al.  Blood pressure effects of the angiotensin II receptor blocker, losartan. , 1995, Archives of internal medicine.

[16]  B. Karlberg,et al.  Effects of modulators of the renin—angiotensin—aldosterone system on cough , 1994, Journal of hypertension.

[17]  G. Reboldi,et al.  Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. , 1994, Hypertension.

[18]  F. Mee,et al.  19 An accurate automated device for home blood pressure measurement at last! The Omron HEM-705CP , 1994 .

[19]  Y. Lacourciére,et al.  Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial. , 1994, American journal of hypertension.

[20]  K. Kubo,et al.  Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl , 1993, The Journal of pharmacology and experimental therapeutics.

[21]  P. Timmermans,et al.  Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.